Key result
Failed thrombolysis in STEMI is linked to ~11% in-hospital mortality and higher renal failure.
Why the study?
This study aimed to determine the clinical and coronary angiographic characteristics associated with successful and failed fibrinolysis in an acute myocardial infarction cohort, and to compare their in-hospital clinical outcomes.
Cohort (n=233)
In STEMI patients treated with tenecteplase or reteplase, failed thrombolysis occurred in 27.9% of cases—correlating with delayed presentation (>6 hours), diabetes, higher Killip class, reduced LVEF, and complex coronary lesions—and resulted in significantly higher in-hospital mortality and morbidity.
Answers are grounded in this paper and cite their sources.
Failed thrombolysis signals higher in-hospital risk in STEMI; hypothesis-generating for risk stratification pending prospective validation.
Aim To determine the clinical and coronary angiographic characteristics associated with successful and failed fibrinolysis in an acute myocardial infarction cohort, and to compare their in-hospital clinical outcomes. Methods A prospective cohort study was conducted among patients presenting with ST-segment elevation myocardial infarction who received fibrinolytic therapy with either tenecteplase or reteplase. Treatment efficacy was evaluated on the basis of the electrocardiogram findings obtained 90 min after fibrinolytic therapy. Results Among the 233 patients enrolled in the study, 168 (72.1%) achieved successful thrombolytic reperfusion, while 65 (27.9%) had failed thrombolysis based on the predefined 90-min electrocardiogram criteria. A symptom-to-thrombolysis interval exceeding 6 h was correlated with failure of reperfusion ( P = .003). Dyspnea at presentation ( P = .003) and Type 2 diabetes mellitus patients ( P = .042) were correlated with unsuccessful thrombolysis. Individuals with Killip II or more had a markedly higher frequency of thrombolytic failure ( P = .0001). A markedly reduced left ventricular ejection fraction (<30%) was more common in patients with unsuccessful thrombolysis than in those with left ventricular ejection fraction >40% ( P = .0023). On coronary angiography, complex Type B2 and Type C lesions were related to unsuccessful fibrinolysis ( P = .035). Patients who failed thrombolysis experienced a greater frequency of adverse in-hospital events, including ventricular tachycardia, cardiogenic shock, acute renal failure, and the need for mechanical circulatory support. Mortality was high in the failed thrombolysis group, occurring in 10.8% of cases ( P = .0001). Acute renal failure was noted in 12.3% of the failed thrombolysis group compared with 4.16% of the successful reperfusion group ( P = .035). Conclusion An ischemic interval exceeding 6 h, dyspnea at presentation, Killip class above I, cardiogenic shock, Thrombolysis in Myocardial Infarction risk score exceeding 4, and Type 2 diabetes mellitus were linked to failure of thrombolytic therapy. Complex coronary anatomy, particularly Type B2 and Type C lesions, was more frequently observed in the failed reperfusion group. Failed fibrinolysis was correlated to have adverse in-hospital outcomes, including ventricular tachycardia, acute renal and heart failure, mechanical circulatory support requirement, and in-hospital mortality.
No takes yet. Share an insight, caveat, or question.
Meegada et al. (2026) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=233). Failed thrombolysis (after tenecteplase or reteplase) vs. Successful thrombolytic reperfusion was evaluated on In-hospital mortality (p=.0001). Failed thrombolysis occurred in 27.9% of STEMI patients and was associated with higher in-hospital mortality and acute renal failure.
Synapse has enriched 10 related papers. Consider them for comparative context: